News | May 29, 2007

Daxor to be Published In Journal of Nuclear Medicine Technology

May 30, 2007 -- Daxor Corp., a medical instrumentation and biotechnology company, announced the June 2007 publication of the Journal of Nuclear Medicine Technology article, "Blood Volume Analysis: A New Technique and New Clinical Interest Reinvigorate a Classic Study."

The article, authored by Dr. Timothy Manzone, Department of Nuclear Medicine, Christiana Care Health System and others features the fundamental concepts of a blood volume measurement and how Daxor's Blood Volume Analyzer BVA-100 and related clinical studies have demonstrated improved clinical management in heart failure, critical care and various other medical conditions.

The Journal of Nuclear Medicine Technology (JNMT) along with the Journal of Nuclear Medicine (JNM) are the most widely read peer-reviewed publications in nuclear medicine and allied disciplines. Practitioners from across the imaging sciences turn to JNMT for peer-reviewed information related to daily clinical practice.

The article reviewed the technical history of blood volume measurement and focused on the difficulty of performing an accurate and timely blood volume measurement until the introduction of Daxor's BVA-100 system.

The authors conclude that "...blood volume analysis reports of today include extraordinarily fundamental clinical parameters we could not previously measure." In addition, they state that facilities which commit to providing an automated blood volume analysis "will be rewarded and will contribute significantly to patient care."

Daxor Corp.manufactures and markets the only FDA-approved semi-automated Blood Volume Analyzer BVA-100 for the measurement of human blood volume. The Daxor BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit.

One of the studies cited within the article discusses how clinical assessment of the volume status of heart failure patients without a blood volume analysis is only correct 51 percent of the time, and how patients who remain volume overloaded have a two-year mortality rate of 55 percent versus a 0 percent mortality rate of patients who are treated to a normal blood volume.

The authors also note the application of blood volume measurement in the management of medical conditions in hematology, cardiology, surgery and critical care medicine.

For more information visit www.daxor.com

Related Content

Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing| May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing| May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing| April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing| April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
highly sensitive troponin testing
News | Cardiac Diagnostics| March 21, 2017
March 21, 2017 — A blood test for a protein called high-sensitivity troponin T, which is released into the bloodstrea
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing| March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing| January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...

The Xprecia Stride Coagulation Analyzer delivers fast, reliable prothrombin time/international normalized ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist. It is the latest INR testing system to enter the market in late 2016. Read the article “Siemens Receives FDA Clearance of Xprecia Stride Coagulation Analyzer.”
 

 

Feature | Point of Care Testing| December 30, 2016 | Ravi Chawat
Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology
Overlay Init